Skip to main content
main-content
Top

05-23-2018 | Insulin | Review | Article

Multinational Consensus: Insulin Initiation with Insulin Degludec/Aspart (IDegAsp)

Journal:
Advances in Therapy

Authors: Sanjay Kalra, Stephen Atkin, Antonio Cervera, Ashok Kumar Das, Ozgur Demir, Tevfik Demir, Md. Fariduddin, Khoa Tuan Vo, Bon Jeong Ku, Ajay Kumar, Zafar A. Latif, Rachid Malek, Bien J. Matawaran, Roopa Mehta, Nam Quang Tran, Araceli Panelo, Sundeep Ruder, Joel Rodriquez Saldana, Khalid A. Shaikh, Amit Shakya, Dina Shrestha, A. G. Unnikrishnan

Publisher: Springer Healthcare

Abstract

Insulin degludec/aspart (IDegAsp) is the first soluble insulin co-formulation, combining a long-acting insulin degludec (IDeg) and rapid-acting insulin aspart (IAsp). In type 2 diabetes patients with oral antidiabetes agent (OAD) inadequacy, insulin initiation with IDegAsp once daily provides superior long-term glycemic control compared to insulin glargine, with similar fasting plasma glucose (FPG) and insulin doses, and numerically lower rates of overall and nocturnal hypoglycemia. Furthermore, in patients with uncontrolled type 2 diabetes previously treated with insulins, IDegAsp twice daily effectively improves glycated hemoglobin and FPG, with fewer hypoglycemic episodes versus premix insulins and basal bolus therapy. In patients with type 1 diabetes mellitus, IDegAsp once daily with two doses of IAsp is a convenient, yet effective, regimen as compared to the conventional 4–5 injection-based basal bolus therapy. IDegAsp is an appropriate and reasonable option for initiation of insulin therapy in both type 1 and type 2 diabetes.

Please log in to get access to this content

Related topics